| Saint Therese At Oxbow Lake | |
| 5200 Oak Grove Parkway, Brooklyn Park, Minnesota 55443 | |
| (763) 493-7000 | |
| Name | Saint Therese At Oxbow Lake |
|---|---|
| Location | 5200 Oak Grove Parkway, Brooklyn Park, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 64 |
| Occupancy Rate | 95.47% |
| Medicare ID (CCN) | 245619 |
| Legal Business Name | Oxbow Lake Care Center Llc |
| Ownership Type | Non Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.
About half of California adults diagnosed with high blood pressure, or hypertension, do not take medication to lower it, researchers reported today at the American Heart Association's 61st Annual Fall Conference of the Council for High Blood Pressure Research.
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.
Nanobodies are a potential therapeutic strategy for treating COVID-19. While many previous studies report nanobodies active against SARS-CoV-2 in vitro, none have been evaluated via animal models' intranasal administration.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.82 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 0.85 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 81.54 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.85 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.17 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.56 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.18 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.44 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.77 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 90.93 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.16 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 9.45 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.12 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.41 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.34 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 81.11 | 82.93 |
News Archive
To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.
About half of California adults diagnosed with high blood pressure, or hypertension, do not take medication to lower it, researchers reported today at the American Heart Association's 61st Annual Fall Conference of the Council for High Blood Pressure Research.
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.
Nanobodies are a potential therapeutic strategy for treating COVID-19. While many previous studies report nanobodies active against SARS-CoV-2 in vitro, none have been evaluated via animal models' intranasal administration.
› Verified 4 days ago
Saint Therese At Oxbow Lake Location: 5200 Oak Grove Parkway, Brooklyn Park, Minnesota 55443 Phone: (763) 493-7000 |